JP2015535256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535256A5 JP2015535256A5 JP2015539867A JP2015539867A JP2015535256A5 JP 2015535256 A5 JP2015535256 A5 JP 2015535256A5 JP 2015539867 A JP2015539867 A JP 2015539867A JP 2015539867 A JP2015539867 A JP 2015539867A JP 2015535256 A5 JP2015535256 A5 JP 2015535256A5
- Authority
- JP
- Japan
- Prior art keywords
- syndrome
- usher
- compound
- pharmaceutically acceptable
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000011580 syndromic disease Diseases 0.000 claims 16
- 208000014769 Usher Syndromes Diseases 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims 6
- 230000002207 retinal effect Effects 0.000 claims 6
- 206010007747 Cataract congenital Diseases 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 201000007737 Retinal degeneration Diseases 0.000 claims 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 238000010276 construction Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000004258 retinal degeneration Effects 0.000 claims 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718593P | 2012-10-25 | 2012-10-25 | |
| US61/718,593 | 2012-10-25 | ||
| US201361775376P | 2013-03-08 | 2013-03-08 | |
| US61/775,376 | 2013-03-08 | ||
| PCT/US2013/066938 WO2014066835A1 (en) | 2012-10-25 | 2013-10-25 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015535256A JP2015535256A (ja) | 2015-12-10 |
| JP2015535256A5 true JP2015535256A5 (enExample) | 2016-12-08 |
| JP6290910B2 JP6290910B2 (ja) | 2018-03-07 |
Family
ID=50545355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539867A Active JP6290910B2 (ja) | 2012-10-25 | 2013-10-25 | ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2912038B1 (enExample) |
| JP (1) | JP6290910B2 (enExample) |
| AU (1) | AU2013334138B2 (enExample) |
| CA (1) | CA2889537C (enExample) |
| ES (1) | ES2693166T3 (enExample) |
| IL (1) | IL238287B (enExample) |
| PL (1) | PL2912038T3 (enExample) |
| TR (1) | TR201816028T4 (enExample) |
| WO (1) | WO2014066835A1 (enExample) |
| ZA (1) | ZA201502654B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2834049C (en) | 2011-04-25 | 2018-05-22 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| AU2013334139B2 (en) * | 2012-10-25 | 2017-08-03 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1435957B1 (en) * | 2001-04-30 | 2009-06-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes |
| CA2585934C (en) * | 2004-10-29 | 2013-09-10 | Abbott Laboratories | Novel pyrazolopyridine urea kinase inhibitors |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| JP2011503103A (ja) * | 2007-11-07 | 2011-01-27 | フォールドアールエックス ファーマシューティカルズ インコーポレーティッド | タンパク質輸送の調節方法 |
| EP2361248B1 (en) * | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| CA2834049C (en) * | 2011-04-25 | 2018-05-22 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| AU2013334139B2 (en) * | 2012-10-25 | 2017-08-03 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome |
-
2013
- 2013-10-25 CA CA2889537A patent/CA2889537C/en active Active
- 2013-10-25 AU AU2013334138A patent/AU2013334138B2/en active Active
- 2013-10-25 TR TR2018/16028T patent/TR201816028T4/tr unknown
- 2013-10-25 ES ES13849803.5T patent/ES2693166T3/es active Active
- 2013-10-25 PL PL13849803T patent/PL2912038T3/pl unknown
- 2013-10-25 JP JP2015539867A patent/JP6290910B2/ja active Active
- 2013-10-25 WO PCT/US2013/066938 patent/WO2014066835A1/en not_active Ceased
- 2013-10-25 EP EP13849803.5A patent/EP2912038B1/en active Active
-
2015
- 2015-04-14 IL IL238287A patent/IL238287B/en active IP Right Grant
- 2015-04-20 ZA ZA2015/02654A patent/ZA201502654B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535257A5 (enExample) | ||
| JP2017186358A5 (enExample) | ||
| PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| JP2013014622A5 (enExample) | ||
| JP2017537066A5 (enExample) | ||
| JP2016518337A5 (enExample) | ||
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| JP2014221779A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2016515522A5 (enExample) | ||
| EP4227304A3 (en) | Thiadiazole analogs and their use for treating diseases associated with a deficiency of smn motor neurons | |
| NZ732154A (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| JP2012107057A5 (enExample) | ||
| EP4241772A3 (en) | Process for the preparation of compounds useful for treating spinal muscular atrophy | |
| JP2013518107A5 (enExample) | ||
| MX343620B (es) | Forma polimorfica de clorhidrato de pridopidina. | |
| PH12015501942A1 (en) | Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders | |
| PH12015502539A1 (en) | Cenicriviroc compositions and methods of making and using the same | |
| JP2013522326A5 (enExample) | ||
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| HK1217092A1 (zh) | 治疗性化合物及其用途 | |
| JP2014503593A5 (enExample) | ||
| WO2016011297A3 (en) | Methods and related compositions for improved drug bioavailability and disease treatment |